11 free paediatric heart surgeries performed by Andhra Hospitals
At a press conference on Sunday (August 3, 2025), Chief of Children's Services and Director of the Hospital Dr. P. V. Rama Rao said that consultant paediatric cardiac surgeon Dr B. R. Jagannath from Shri Madhusudan Sai Hospital at Muddenahalli in Bengaluru along with Andhra Hospitals cardiac surgical team led by Dr. Nageswara Rao, completed 11 free heart surgeries.
The team performed very complex heart surgeries for conditions like Total Anomalous Pulmonary Venous Drainage (TAPVD), Partial Anomalous Pulmonary Venous Drainage (PAPVD), TOF and PA banding among other surgeries, he said, adding that the success rate of the surgeries was nearly 99% and which is because of the team effort. He said so far, the hospital had successfully performed more than 4,800 cardiac surgeries and interventions.
Representatives of the Healing Little Hearts, UK team, have visited the hospital 34 times so far and many complex heart surgeries were performed with their association, he added.
Senior paediatric cardiologist Dr. Vikram, Paediatric cardiologist Dr. Sk. Moinuddin Chisty, senior cardiac surgeon Dr. Nageswara Rao, senior cardiac anaesthetist Dr. Ramesh and cardiologists Dr. Raghuram, and Dr. Tirupathi Rao were also present at the press meet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.
Mint
3 hours ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.
